Hematopoietic cell transplant (HCT) is a life-saving therapy for many malignant and non-malignant bone marrow diseases. Associated morbidities are often due to transplant-related toxicities and infections, exacerbated by regimeninduced immune suppression and systemic incursion of bacterial products. Patients undergoing myeloablative conditioning for HCT become endotoxemic and display blood/plasma changes consistent with lipopolysaccharide (LPS)-induced systemic innate immune activation. Herein, we addressed whether patients scheduled for HCT display differences in recognition/response to LPS ex vivo traceable to specific single nucleotide polymorphisms (SNPs). Two SNPs of LPS binding protein (LBP) were associated with changes in plasma LBP levels, with one LBP SNP also associating with differences in efficiency of extraction and transfer of endotoxin to myeloid differentiation factor-2 (MD-2), a step needed for activation of TLR4. None of the examined SNPs of CD14, bactericidal/permeability-increasing protein (BPI), TLR4 or MD-2 were associated with corresponding protein plasma levels or endotoxin delivery to MD-2, but CD14 and BPI SNPs significantly associated with differences in LPS-induced TNF-a release ex vivo and infection frequency, respectively. These findings suggest that specific LBP, CD14 and BPI SNPs might be contributory assessments in studies where clinical outcome may be affected by host response to endotoxin and bacterial infection.
Introduction
Hematopoietic cell transplant (HCT) is a life-saving therapy for many malignant and non-malignant bone marrow diseases. HCT regimen-related toxicities and post-transplant infections contribute significantly to post-transplant morbidity and mortality. 1, 2 Post-transplant inflammation and infections are likely due to the combined effects of conditioning regimen-induced immune suppression and tissue injury, which permit translocation of bacteria and bacterial products to the systemic circulation. 3, 4 Lipopolysaccharide (LPS), often referred to as endotoxin, is an abundant and potently pro-inflammatory constituent of the outer membrane of Gram-negative bacteria, and humans undergoing myeloablative HCT are frequently endotoxemic. 5 LPS leakage across damaged intestinal epithelium may be a significant contributor to the so-called 'cytokine storm' after myelo-ablative HCT. 6 Systemic LPS induces production of a range of pro-inflammatory cytokines and chemokines, including TNF-a, 7 CCL2, CXCL10 and CCL5, 8 as well as activation of the inflammasome complex and IL-1 b secretion. 9 The potential of pM concentrations of plasma endotoxin to contribute to immune pathology in HCT patients reflects the remarkable potency of the immune-stimulating properties of LPS in humans. This potency depends on the ordered actions of several host extracellular and cell surface proteins, including LPS-binding protein (LBP), membrane and soluble forms of CD14, secreted or receptor-associated myeloid differentiation factor-2 (MD-2) and TLR4, which together make possible host detection and response to pM concentrations of endotoxin. In brief, LBP catalyzes extraction and transfer of individual molecules of endotoxin from the outer membrane of Gram-negative bacteria (or from aggregates of purified endotoxin) to CD14, followed by transfer of activating endotoxin to MD-2 and engagement and activation of MD-2/ TLR4 complexes. [10] [11] [12] This catalytic role of LBP is most pronounced at relatively low LBP concentrations. When present in higher concentrations, LBP can react stoichiometrically with endotoxin and endotoxin/CD14 complexes to promote clearance of endotoxin without engagement and activation of TLR4. 13, 14 While the ability of humans to respond sensitively and robustly to endotoxin is important for timely mobilization of host defense responses against invading Gram-negative bacteria, it also increases the risk of potentially harmful immune responses.
Given the potent bioactivity of LPS, humans express a variety of mechanisms to counteract the effects of endotoxin and endotoxemia; these serve to blunt TLR4 signaling and/or skew cellular responses toward production of anti-inflammatory rather than proinflammatory mediators. Such mechanisms include (a) modification of MD-2 and TLR4 surface expression; 15 (b) alteration of relative molar ratios of LBP, CD14 and MD-2; 11, 16 (c) enzymatic detoxification of LPS; 17 and (d) neutralization of endotoxin by cationic antimicrobial proteins and peptides, 18 such as the bactericidal/permeability-increasing protein (BPI), which has high affinity for LPS 12 and is found in high concentrations in human neutrophils. Other factors involved in the recognition of, and response to, bacterial compounds include TLR2 (recognizes bacterial lipoproteins), and TLR adaptor molecules myeloid differentiation primary response gene 88 (MyD88) and MyD88 adapter-like Mal/TIRAP, which enable downstream signaling following TLR engagement.
The complexity of host mechanisms mediating and regulating host recognition and response to endotoxin is likely to result in variability between individuals in their response to plasma endotoxin.
One possible source of variability between individuals in levels and/or activity of pertinent LPS recognition and signaling proteins could originate from allelic differences deriving from single nucleotide polymorphisms (SNPs). Among these, certain SNPs within the BPI, CD14, LBP, Mal/TIRAP, MD-2, TLR2 and TLR4 genes are associated with genotype-dependent in vitro, ex vivo and/or in vivo (clinical) phenotypes (see Table 1 ). It is therefore conceivable that effects of endotoxemia in HCT (or other) patients could be influenced by differences between patients in their genotypes for specific LPS recognition or signaling proteins. To date, there have been no reported studies of the possible association of specific SNP genotypes of plasmaderived endotoxin recognition proteins with the efficiency of recognition and response to plasma LPS.
To address the hypothesis that individual HCT patients differ in their recognition of and response to plasma endotoxin due, at least in part, to SNP-derived genotypic differences in LPS recognition proteins, we designed a new observational cohort study and characterized potentially relevant SNPs of LBP, CD14, MD-2, TLR4, BPI and Mal/TIRAP, and the possible relation of specific SNP genotypes to (a) plasma protein levels; (b) plasma-dependent extraction and transfer of endotoxin to MD-2; and (c) responses to LPS in whole blood.
These studies have revealed specific LBP and CD14 SNPs that associate with alterations in plasma protein levels, plasma-dependent extraction and transfer of activating endotoxin to MD-2 (LBP), and activation of MD-2/TLR4 (CD14). In addition, our studies have revealed a potential association of a BPI SNP with post-transplant infection frequency, suggesting that these SNPs should be monitored in future clinical studies where clinical outcome may be affected by host response to plasma endotoxin. Table S1 ). 19 Supportive care was per institutional routine. 20, 21 Prophylactic oral non-absorbable antibiotics were administered: bacitracin and polymyxin (BWH) or vancomycin (BCH). Blood counts and cultures were performed in clinical laboratories.
Materials and methods
Cohort II. Patients (n ¼ 201) being evaluated for myeloablative or non-myeloablative allogeneic, autologous or syngeneic HCT from 2009 to 2011 at the Dana-Farber Cancer Institute (DFCI), BWH, the University of Iowa and Veterans' Administration Medical Center, Iowa City (UIVAMC) were recruited prospectively onto an IRB-approved study ( Supplementary Table S2 ). Onetime peripheral blood samples were taken before transplant (B-baseline) for SNP genotyping and in vitro assays. DFCI/BWH care guidelines were identical to those of Cohort I. Supportive care was according to institutional routine 20,21 at UIVAMC (prophylactic antibiotics used were levofloxacin 500 mg daily or ciprofloxacin 500 mg q12h). Infection data were derived from Center for International Blood & Marrow Transplant Research day 100 reports. We did not have the statistical power to analyze the effects of SNPs on veno-occlusive disease or diffuse alveolar hemorrhage/interstitial pneumonia owing to low frequencies of these clinical complications in our patient population ( Supplementary Table S3 ).
Blood collection and plasma preparation
Peripheral blood samples were drawn into K2-EDTA or sodium heparin vacutainer tubes (Becton-Dickinson, San Jose, CA, USA). Cohort I samples were collected at baseline (B-before myelo-ablation), d 0 (d 0-day of transplant prior to cell infusion) and d 7, 14, 21 and 28, while Cohort II samples were drawn after enrollment and prior to onset of conditioning. Indicated volumes were centrifuged at 1200 g for 5 min at 4 C, and aliquots of the recovered plasma stored in pyrogenfree tubes (Denville Scientific, Metuchen, NJ, USA) at À20 C.
LPS-induced TNF-release ex vivo
Samples of EDTA blood (Cohort II) were stimulated with 1 ng/ml LPS (List Laboratories, Campbell, CA, USA) in Modified Eagle Medium (Invitrogen, Grand Island, NY, USA) control or medium only, and incubated in pyrogen-free 1.5-ml tubes for 4 h at 37 C, rotating end-over-end, prior to collection of the extracellular medium for subsequent TNF-a ELISA (R&D Systems, Minneapolis, MN, USA or BD BioSciences, San Jose, CA, USA).
ELISAs and measurement of chemokines
ELISAs were used to measure TNF-a, sCD14, sTNF-RI, sTNF-RII (all R&D Systems), BPI and LBP (HyCult, Uden, the Netherlands), according to the manufacturers' instructions. sMD-2 was measured by a customized ELISA as previously described. 22 CCL2, CCL5 and CXCL10 were measured by flow cytometry (MoFlo; DakoCytomation, Glostrup, Denmark) using fluorescent beads covalently linked to corresponding mAbs (Cytometric Bead Array BD Flex Sets; BD BioSciences) and results analyzed with Summit v4.0 software (DakoCytomation).
Quantitative real-time PCR arrays
Peripheral blood (2.5 ml) was collected into PAXgene tubes (PreAnalytiX/Qiagen, Hilden, Germany). Total mRNA was isolated using the PAXgene blood RNA kit and the RNeasyMinElute cleanup kit, followed by cDNA synthesis using the RT 2 First Strand Kit (all Qiagen) according to the manufacturer's instructions. The equivalent of 1 ng RNA/well was assayed using a customized 84-gene signaling pathway PCR array (Qiagen), according to the manufacturer's instructions. Total RNA was normalized using five housekeeping genes and data analyzed using the ÁÁC t method. 23 Mean fold changes in gene expression in a given patient were calculated by comparing mRNA levels at baseline (B) with subsequent time-points (d 0 and d 14), with >fourfold increases and decreases classified as meaningful up-and down-regulation, respectively.
SNP genotyping
SNPs were genotyped by allelic discrimination using TaqMan assays following the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). Two SNPs were genotyped by direct sequencing: rs6099106 as previously described. 24 PCR reactions were conducted as previously described 25 and sequencing was performed by Functional Biosciences (http://functio nalbio.com/web/) Rationale for SNP selection included significant association in previous publications, known missense mutations or haplotype coverage in relevant pathway genes (Table 1) . Observed SNP frequencies within Cohort II are shown in Table 2 .
Assay of plasma-dependent extraction and transfer of endotoxin to MD-2
Typical incubation mixtures contained 85% (v/v) human plasma/EDTA spiked with 5% (v/v) purified aggregates of metabolically-labeled meningococcal lipooligosaccharide (LOS) 26, 27 {[ 3 H]LOS agg (500 cpm; 100 pM (500 pg LOS/ml), final concentration} and 10% (v/v) insect cell (Hi5)-conditioned cell medium with or without His 6 -sMD-2 [27] [28] [29] [$ 5 nM (100 ng bioactive sMD-2 monomer/ml), final concentration] in a total volume of 0.2 ml. Human plasma samples were either from individual donors/patients or from a pool of healthy donors used as a control for each assay. All plasma samples were stored in aliquots at -80 C and used after one freeze/thaw. Plasma + [ 3 H]LOS agg AE His 6 -sMD-2 were incubated for 15 min at 37 C followed by dilution 2 Â with PBS, addition of 20 ml of a 1 : 1 slurry of Ni 2+ FF-Sepharose and incubation on a rotating wheel at 4 C for 60 min. After sedimentation of the Ni 2+ FF-Sepharose gel by centrifugation at 10,000 g for 30 s, the supernatant was removed. The gel was washed once with 0.4 ml icecold PBS. The recovered supernatants and resuspended gel (in PBS) were transferred to counting vials to measure the recovered [ 
Statistical analyses
Samples with undetectable analytes were assigned a value at half the lower limit of detection. 
Results

Plasma endotoxin during myelo-ablative HCT is followed by systemic inflammatory responses
We recently reported a high incidence of endotoxemia in HCT patients enrolled in an observational cohort study 19 (Cohort I) with elevated levels of plasma LPS manifest by the completion of myeloablative conditioning (d 0). Changes in monocyte cell surface levels of membrane (m)CD14 (diminished) and TLR4 (increased), 19 and in plasma levels of monocyte chemotactic protein 2 (CCL2; Figure 1a ) were also manifest on d 0, consistent with acute host responses to plasma endotoxin during myeloablative conditioning. The regimen-induced monocyte nadir at d 0 and d 7 corresponded with a significant decrease in levels of spontaneous TNF-a production in whole blood ex vivo on those days (Figure 1b, c) , with both changes normalizing by d 21. Plasma levels of the chemokine CCL5 followed a similar pattern (Figure 1d ), contemporaneous with nadirs and normalization in absolute neutrophil count, platelet counts and BPI, and a spike in IL-6 production. 19 In contrast, plasma levels of LBP rose rapidly, peaking at d 7 and d 14, (Figure 1e ), while levels of soluble TNF-a receptors 1 and 2 (sTNRF1/2), sCD14 and the IFN-responsive cytokine CXCL10 also increased. However, these changes were more gradual and sustained (Figure 1f -h). No changes in sMD-2 or TLR2 were observed (data not shown). Measurement of peripheral blood levels of mRNA derived from a customized panel of 84 inflammatory genes provided further evidence suggesting in vivo activation of cellular inflammatory responses by d 0 (Figure 2a ; Supplementary Table S4 ) that generally returned to baseline levels (i.e. mRNA levels prior to initiation of myeloablation) by d 14 (Figure 2b) . Species of mRNA that were elevated at d 0 relative to cells collected at baseline and at d 14 included multiple genes involved in the LPS-TLR4 signaling axis (LBP, CD14, MD-2, TLR4 and MyD88), as well as inflammasome signaling (CASP1, IL1B) and the acute phase response (CRP, LBP) ( Figure 2c ). The in vivo elevation of whole blood mRNA levels for these inflammatory genes is especially remarkable given the marked reduction in blood monocyte levels and ex vivo whole blood responses to systemic LPS (e.g. secretion of TNF-a) manifest by d 0 (Figure 1b, c) . Taken together, these findings suggest acute in vivo endotoxin-induced innate immune activation in patients undergoing myeloablative conditioning prior to HCT.
Associations of specific genotypes of LBP with differences in LBP protein plasma levels
Four LBP SNPs were analyzed: two SNPs located within the structural gene of LBP, giving rise to structural alterations in LBP (rs2232613 Pro333Leu; rs2232618 Phe436Leu) and two SNPs located in the promoter region of LBP (rs2232571 and rs2232582; Table 1 ). Genotype-associated differences in plasma levels of LBP protein were observed for rs2232571 and rs2232613. These differences were statistically significant for the more frequently represented genotypes in the Cohort II patient population (rs2232571: CT > TT; rs2232613: CC > CT) (Figure 3a, c) . In contrast, no statistically significant differences in plasma LBP protein levels were detected for the other two LBP SNPs examined (Figure 3b, d) .
Differences in plasma-dependent extraction and transfer of endotoxin monomer to MD-2 associate with specific LBP genotypes
Maximal potency of activation of TLR4 by endotoxin depends on sequential interactions of endotoxin with LBP, membrane (m) and/or soluble (s) CD14 and MD-2 (secreted or, more typically, associated with TLR4 on cell plasma membranes). LBP catalyzes extraction and transfer of individual molecules of endotoxin from aggregated forms of endotoxin to sCD14 or mCD14, which, in turn, allows more efficient transfer of TLR4-activating endotoxin monomers to MD-2 and MD-2/TLR4 complexes. [10] [11] [12] To measure the extraction and transfer of endotoxin to MD-2, we designed a novel assay in which individual plasma samples were spiked with recombinant His 6 -MD-2 and aggregates of metabolically labeled, purified [ 3 H] endotoxin of very high and virtually uniform specific radioactivity (see 'Materials and methods'). 13, 25, 30 LBP SNP rs2232613 showed genotype-associated differences in endotoxin extraction and transfer to MD-2 that seemed inversely related to genotype-associated mean plasma LBP levels (compare Figures 3c and 4c ). Only the differences in MD-2 transfer between the most frequently represented genotypes of LBP rs2232613 (CT > CC; Figure 4c ) were statistically significant. The other three LBP SNPs were not associated with any significant differences in endotoxin extraction and transfer to MD-2 (Figure 4a, b, d ).
CD14 genotypes confer differences in cell activation by LPS in whole blood ex vivo
Two CD14 SNPs (rs2569190 and rs2569191) were analyzed, the former located within the promoter region of the CD14 gene (Table 1) . Neither genotype-associated differences in CD14 protein levels in plasma nor in plasma-dependent extraction and transfer of [ 3 H] endotoxin to His 6 -MD-2 were observed (Figure 5a-d) .
However, comparison of LPS-induced secreted TNFa levels in vitro for CD14 SNPs showed a significant difference in TNF-a production between the AG and AA alleles for CD14 SNP rs2569190 (Figure 5e ) and between the CC genotype of CD14 SNP rs2569191 compared with either the CT or the TT genotypes (Figure 5f ). No effect on LPS-induced TNF-a production from peripheral blood was observed for any of the other SNPs investigated, including TLR4 SNPs rs4986790 and rs4986791 (data not shown).
BPI SNP rs4358188 genotype is associated with increased frequency of infection following autologous and syngeneic HCT Infection outcome data for patients in Cohort II were available for all patients that underwent HCT (n ¼ 188; Supplementary Tables S2 and S3 ). In order to assess whether the SNPs studied were associated with differences in post-transplant infections, we restricted analysis to those patients receiving autologous and syngeneic transplants and, thus, in contrast to those receiving allogeneic cells, retained their SNP genotypes in the hematopoietic compartment (n ¼ 54). Of the 54 patients receiving autologous or syngeneic transplants, 21 patients had documented infections, all of whom experienced bacterial infection alone, or bacterial plus either viral or fungal infection (Table 3 ). Four BPI SNPs were analyzed: two located within the structural gene of BPI, giving rise to structural variants of BPI (rs1341023 Ala16Val; rs4358188 Glu216Lys), one located within the 3'-UTR (rs1131847) and one located within an intron (rs6099106) ( Table 1) . Consistent with prior studies linking BPI genotype with risks of infection, 31, 32 there was a decreasing association of infection rates with BPI SNP rs4358188 genotypes AA, AG and GG (n ¼ 54; Table 4 ). The limited numbers of patients with infections precluded a sub-group analysis by type Supplementary Table S4 ).
of bacterial infection. No apparent differences in SNP genotype distributions and infection frequency in autologous and syngeneic HCT recipients were observed for the other three BPI SNPs or for CD14, LBP, Mal/TIRAP, MD-2, TLR2 or TLR4 SNPs (data not shown).
Discussion
In this study we observed significant changes in multiple innate immune mediators, including TNF-a, CCL2 and CCL5, as well as components of the LPSdetection machinery at the mRNA (CD14, LBP, MD-2, MyD88, TLR4) and protein (LBP, sCD14) levels in patients undergoing myeloablative HCT. Based on these and our previous observations for BPI, 19 we studied another prospective cohort of patients undergoing HCT to analyze the potential effects of different SNP genotypes in BPI, CD14, LBP, Mal/TIRAP, MD-2, TLR2 and TLR4 on protein levels, functionality and infection outcomes in this population. We observed two distinct temporal patterns of change in Cohort I. There were components that increased or decreased at early-to-mid-range time points (d 0-d 14) with rapid recovery and those that increased at later time points (d 14-d 28). Components in the early d 0-d 14 group, which includes CCL2, CCL5 and spontaneously secreted TNF-a, corresponded closely to nadirs and recovery of platelets 19 and monocytes, and signify shifts similar to those we have reported previously for neutrophils and neutrophil constituents. 19 We hypothesize that changes following the second pattern, such as the d 14-d 28 increases in LPS receptor components CD14 and LBP, as well as sTNFR1/2 and CXCL10, which are up-regulated in response to Gram-negative bacteria, 8 are suggestive of inflammatory responses that might be influenced by the pattern of hematopoietic ablation and recovery. These can be further exacerbated by the presence of systemic endotoxin, 19 and potentially by clinically evident post-transplant infections.
It should be noted that levels of endotoxemia observed during this time in the HCT patients in Cohort I ranged from intermediate levels of endotoxin activity units (! 0.4 and < 0.6; 4/18, 22%) to high levels (! 0.6; n ¼ 12/18, 67%), 19 as classified for clinical relevance in the 2003 Multi-Center Endotoxin Detection in Critical illness (MEDIC) trial, where endotoxin units ! 0.6 conferred a significantly higher risk of developing severe sepsis within 24 h of testing in Intensive Care Unit patients. 33 At the mid-to-low range of concentrations, the immune-stimulatory activity of plasma endotoxin is likely more dependent on the levels and activity of several host proteins that regulate delivery of LPS to MD-2/TLR4 and/or cell signaling following TLR4 activation. By monitoring several SNPs within genes encoding these host proteins in a second observational cohort (Cohort II), we have found certain SNP Figure 5 . Association of CD14 SNPs rs2569190 and rs2569191 with altered LPS-induced TNF production ex vivo. Cohort II: plasma samples corresponding to CD14 SNPs rs2569190 (a, c, e) and rs2569191 (b, d, f) are shown. sCD14 protein levels were assessed by ELISA (a, b), ex vivo plasma-dependent extraction and transfer of endotoxin monomer to MD-2 was measured and represented as relative LOS capture as described in the 'Materials and methods' (assay detection limit signified by dotted line 1%) (c, d). Extracellular TNF-a accumulation measured by ELISA following ex vivo stimulation of whole blood with LPS (1 ng/ml) for 4 h (assay detection limit signified by dotted line ¼ 7.8125 pg/ml) (e, f). Values represent median and 5-95 percentile with outliers shown for raw data (a-d) and of log-transformed values labeled in original units (e, f). Only groups of n ! 8 were considered for statistical comparisons. For two-way comparisons (c, d), two-tailed t-test or Mann-Whitney test was applied (parametric or non-parametric distributions, respectively). For three-group analyses (a, b, e, f), Kruskal-Wallis test with Dunn's Multiple Comparisons Test was applied. Statistical significance is indicated as *P < 0.05. LLD: lower limit of detection.
genotypes of LBP and CD14 that modify the plasma concentrationsof these proteins (LBP SNPs rs2232613 and rs2232571) and/or the handling (LBP rs2232613) and response to plasma endotoxin ex vivo (CD14 SNPs rs2569190 and rs2569191).
Our findings that LBP SNPs rs2232571 and rs2232613 were associated with changes in plasma LBP protein concentrations confirm two previous reports linking rs2232613 and rs2232571 to LBP serum 34 and plasma 35 levels, respectively. Detailed mapping and mutational studies of the LBP promoter region have suggested an effect of the C/T substitution in SNP rs2232571 on the function of the CAAT box at position À778 and thus on LBP promoter activity. 36 By showing effects on mean plasma LBP concentrations, our findings ( Figure 3a) and those of an earlier study 35 support the hypothesis that LBP SNP rs2232571 affects the LBP promoter, with SNP genotype frequency ranking TT > CT > CC inversely relating to protein levels (CC > CT > TT). It is interesting to note that although a common four-SNP risk haplotype in the 5'-flanking region of the LBP gene (positions À1978 to À763, rs2232571 is at position À836) has been linked to an increased risk for severe sepsis, 37 we did not find any association of this SNP with post-transplant infection frequency (albeit in a small cohort). How SNP rs2231613 confers alterations in circulating LBP protein levels (Figure 3c ) is less clear, but it is conceivable that the Pro333Leu substitution leads to structural alterations affecting protein secretion, stability and/or plasma half-life. Whatever the basis of SNP rs2232613 effects on protein levels, this structural alteration appears to be associated with different handling of plasma endotoxin, as manifested ex vivo by genotypeassociated differences in extraction and efficiency of TLR4-activating endotoxin monomer to MD-2 ( Figure  4c ). The apparently inverse relation within this LBP SNP of genotype-associated differences in mean plasma LBP levels and plasma-dependent endotoxin delivery to MD-2 is consistent with in vitro and in vivo data showing that elevated LBP concentrations blunt-rather than promote-delivery of activating endotoxin to MD-2/ TLR4 and endotoxin-induced inflammation. 16 The elevated plasma LBP levels observed in all HCT patients by d 7-d 14 (Figure 1e ) may also contribute to blunting of blood cell responses to endotoxemia that can persist for at least 28 d. It should be noted, however, that our data do not reveal an overall correlation between plasma LBP protein levels and plasmadependent formation of endotoxin/MD-2 complexes (Spearman correlation, P ¼ 0.5), suggesting a possibly added role of the structural alteration of LBP conferred by the rs2232613 SNP and/or other variables in plasma composition. As no genotype-associated differences in plasma-dependent endotoxin/MD-2 formation were observed within the examined SNPs of CD14, MD-2 and BPI, these three endotoxin-binding proteins-as plasma constituents-do not appear to contribute to differences at baseline in handling of plasma endotoxin by patients scheduled for HCT.
Others have shown both CD14 SNPs rs2569190 and rs2569191 to be associated with alterations in CD14 protein levels in blood 38 and plasma 39 without showing associations with altered LPS-induced TNF-a production ex vivo. 40 Inversely, we did not observe any associations of CD14 SNPs rs2569190 and rs2569191 with sCD14 protein levels in plasma, but ex vivo stimulations of peripheral blood with LPS revealed significant differences in secreted TNF levels when comparing the AA and AG genotypes for rs2569190 and the CC genotype compared with either CT or TT for rs2569191. These apparent contradictions need to be considered in the context of differences in population demographics, age and disease context: Munthe-Kaas et al. 39 showed that rs2569190 and rs2569191 were associated with serum sCD14 protein levels in Norwegian children up to 2 yrs of age, but not in those older than 2 yrs of age. Others have shown that increased CD14 promoter activity in vitro with rs2569190 and rs2569191 did not translate into increased mRNA levels in population of healthy Caucasian blood donors, 41 and that rs2569190 association with increased sCD14 levels in blood was observed before, but not after, LPS exposure in healthy volunteers in Belgium. 38 Nearly 15% of our study subjects showed heterozygous expression of TLR4 SNP variants Asp299Gly and Thr339Ile derived from the SNP variants A/G and C/T, respectively, but there were no significant differences in cellular response to LPS associated with expression of these TLR4 variants in our whole blood assays. This is in agreement with ex vivo human whole-blood stimulation assays 42 and consistent with recent evidence indicating that the greatest functional effects of expression of these TLR4 variants are manifest in settings containing relatively low levels of plasma proteins and in cells expressing cell surface TLR4 without MD-2. 27, 43 Taken together, we speculate that the differences in cellular response to LPS in whole blood that we see associated with specific CD14 genotypes could reflect differences in mCD14 (rather than soluble CD14), thereby affecting the efficiency of delivery of activating endotoxin to MD-2/ TLR4 and/or cell signaling following TLR4 activation.
Among the BPI SNPs examined, we saw no genotype-associated differences in either plasma protein levels or ex vivo handling of plasma endotoxin. The examined SNPs include a SNP located within the 3 0 UTR of the BPI gene previously reported to show genotype-associated differences in plasma BPI levels in a study of diabetics. 44 Notably, the plasma BPI levels we measured were about five-fold lower than those reported in the aforementioned study, raising the possibility of additional ethnic and disease-specific or other pathophysiological variables that could affect plasma BPI levels. Given the very low plasma BPI concentrations we measured in HCT patients, it is not surprising that little or no effect of genetic variation in BPI was observed in either of the two ex vivo assays performed. In line with previous observations 31, 32 and within the limits of a relatively small number of autologous or syngeneic HCT patients (n ¼ 54) with documented infection (n ¼ 21), we observed a potential association of one BPI variant (AA genotype within rs4358188) with overall infection frequency among HCT patients post-transplant that should be further validated independently in a larger cohort. If validated, such an effect could conceivably reflect extravascular roles of BPI following expression on mucosa/epithelia and/or secretion from recruited and activated neutrophils at sites of microbial infection. 45, 46 In summary, our findings suggest that recognition and response to plasma endotoxin may be modified by SNP-derived variables in the levels and/or activity of plasma LBP and cell surface CD14 manifest at baseline in patients scheduled for HCT. Additional and more detailed studies will be needed to test whether the associations we have observed reflect effects of the specific LBP and CD14 SNPs on protein expression, secretion, surface expression, half-life or on specific functional properties of these proteins. However, even in the absence of this more detailed mechanistic knowledge, we suggest that future clinical studies where outcome may be affected by host responses to endotoxin, including observational and treatment studies in myeloablative HCT, 47 measure the specific LBP, CD14 and BPI SNPs functionally implicated in this study.
